Sun Pharma Q1 Results: Net profit falls 20%; revenue from operations rises

Sun Pharmaceutical Industries on Thursday announced its first-quarter results, posting a 20 per cent decline in its profit after tax (PAT).

In its Q1 earnings, the large-cap pharmaceutical firm reported a 19.64 per cent year-on-year (YoY) decline in its consolidated net profit for the quarter ended June 30, 2025.

The company posted a net profit of Rs 2,278.6 crore during the April–June quarter this year, down from Rs 2,835.6 crore recorded in the same period last year.

Add Zee Business as a Preferred Source

Despite a decline in net profit, the company, however, reported an increase in its revenue from operations.

During the quarter, revenue increased by 9.47 per cent to Rs 13,851.4 crore in the first quarter of the current financial year, compared to Rs 12,652.75 crore during the corresponding period last year.

The company's total income rose to Rs 14,315.8 crore YoY from Rs 13,185.3 crore.

Meanwhile, the pharma giant reported an EBITDA of Rs 4,302 crore for the quarter, an increase from Rs 3,608 crore in the same quarter last year.

The EBITDA margin rose to 31.06 per cent YoY from 28.51 per cent.

Profit before tax for the quarter was Rs 3,172.8 crore, compared to Rs 3,423.5 crore in the year-ago period.

Total expenses stood at Rs 10,325.1 crore for the quarter, up from Rs 9,761.8 crore in the same quarter of the previous year.

Sun Pharma stock dips

On Thursday, the company's stock ended the trading session almost 2 per cent lower to RS 1,700 on BSE.